Moleculin Biotech, Inc. (MBRX) vs Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
A side-by-side comparison of Moleculin Biotech, Inc. and Shuttle Pharmaceuticals Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MBRX
Moleculin Biotech, Inc.
$0.45HealthcareDelayed quote: Oct 6, 2026, 1:51 PM EDT
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
$4.08HealthcareDelayed quote: Oct 6, 2026, 1:52 PM EDT
Total return — MBRX vs SHPH
growth of $100 · dividends reinvested · last 4yMBRX -99.9% (-82.9%/yr)SHPH -100.0% (-91.5%/yr)MBRX compounded faster over this window
Log scale — wide-divergence pair
MBRX SHPH
MBRX vs SHPH: by the numbers
- •SHPH is the larger company ($2M vs $2M market cap).
Metrics side by side
Valuation
| Metric | MBRX | SHPH |
|---|---|---|
| P/B ratio | 0.21 | 0.12 |
Profitability
| Metric | MBRX | SHPH |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -261.73% | -53.49% |
| ROIC | -242.25% | -58.05% |
Growth (annualized)
| Metric | MBRX | SHPH |
|---|---|---|
| Total return CAGR (5Y) | -78.48% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.